Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 3/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.35 |
| ▸ | RHOA | P61586 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | GIPR | P48546 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18609279 | 1.00 | MAPK14 (0.36) | MAPK14UBE2MDCUN1D1RHOAALDH1A1 | |
| SCHEMBL14959101 | 0.94 | MAPK14 (0.37) | MAPK14UBE2MDCUN1D1RHOAALDH1A1 | |
| SCHEMBL21163857 | 0.94 | MAPK14 (0.37) | MAPK14UBE2MDCUN1D1RHOAALDH1A1 | |
| SCHEMBL17805437 | 0.94 | MAPK14 (0.37) | MAPK14UBE2MDCUN1D1RHOAALDH1A1 | |
| SCHEMBL18790204 | 0.94 | MAPK14 (0.37) | MAPK14UBE2MDCUN1D1RHOAALDH1A1 | |
| SCHEMBL14960519 | 0.94 | MAPK14 (0.37) | MAPK14UBE2MDCUN1D1RHOAALDH1A1 | |
| SCHEMBL14959097 | 0.93 | MAPK14 (0.38) | MAPK14UBE2MDCUN1D1RHOAALDH1A1 | |
| SCHEMBL14959090 | 0.91 | MAPK14 (0.37) | MAPK14UBE2MDCUN1D1RHOAALDH1A1 | |
| SCHEMBL20879804 | 0.90 | MAPK14 (0.37) | MAPK14UBE2MDCUN1D1RHOAALDH1A1 | |
| SCHEMBL12176249 | 0.90 | MAPK14 (0.37) | MAPK14UBE2MDCUN1D1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102258-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-4015504-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3508477-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3508477-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9573897-B2 | C5AR antagonists | CHEMOCENTRYX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-3078658-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160229802-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-08-11 | — | — | US | disclosed |
| EP-2381778-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9126939-B2 | C5AR antagonists | CHEMOCENTRYX, INC. | 2015-09-08 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114017-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MAPK14 3989/4885UBE2M 4268/4885DCUN1D1 1926/4885 |
| US-20160229802-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MAPK14 3989/4885UBE2M 4268/4885DCUN1D1 1926/4885 |
| US-20230102258-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MAPK14 3989/4885UBE2M 4268/4885DCUN1D1 1926/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MAPK14 3989/4885UBE2M 4268/4885DCUN1D1 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.